Member Info for Aldebaran

Trust in management evaporated.

Competition increasing

Not discounting is a strategic mistake in my view to protect margins at a time when sales are missing my a country mile

Sorry but I see 150p here as a target price not a penny more. Too many head winds and you can no longer trust a word management say

Hi code junkie I've re looked at the chart I don't see anything other than a rejection of the 50dma and a drop below the coveted 34p support line. As a result I am expecting a pullback to 25p area.

However their is a fairly large gap below that which is at 17p. Im not saying it will close but if price continues to drop in anticipation of the placing and gets near it, you can be sure the placing will give it the nudge it needs to close that gap its interesting watching without being emotionally or financially involved. Note also that the 200dma is currently sitting inside that gap window so we would have a bit of confluence there also.

Never say never

Close a move 925p would signal a breakout of the VCP i mentioned earlier. It'll happen today or tomorrow. Probably today as the likelihood of P3 update landing grows.

Boom is a cr happy little podcast company no use whatsoever waifer thin margins and in a highly competitive sector. Its egregiously overvalued. If any of our resident shorter want a better idea to short id start with audiboom

Understood JHFH. Let's put it this way, regardless of what is past, the future is bright for HEMO in my opinion. We wouldn't be here otherwise.

JHFH, I dont think anyone is denying that HEMO has turned a corner..I for one wouldn't be here if it hadn't. The point is one of the fan club moorscloud is posting ball axe saying how great a job Vlad has done to get this company "investment ready". In mine and others opinion he's been fortunate enough to have the likes of you approaching him and offering advice etc... historically he has had zero regard for shareholders and the valuation of the company. He just wants to get his head down and focus on the science. That is what he's good at and seemingly now the rewards will come but its definitely nothing to do with his business acumen or his deliberate focus on HEMO becoming business ready. Support from you guys has fell into his lap.

He should be CMO or CSO and appoint a business savvy CEO for the commercialisation phase if he intends to go alone. Which he doesn't and won't be able to so HEMO will be snapped up and puts an end to what has been a nightmare thus far for long term holders. A profitable end I might add but could and should have been so much better

Posts are there to see Haywain, why don't you go find them.

Think you'll see i was raising my concerns about Vlad focusing only on the science even back then. I cant delete my posting history so its there.

Let it roll, one good thing about LSE is it stores your posting history. If you can be bothered, go back and check my posts from around 5 years ago I think it was. The evidence is there. Or just continue in your ignorance believing im a shorter etc I don't really care.

Also, I've never said I'm a businessman and not pretended to be one. I am a reasonable trader though and half decent investor.

For people saying HEMO can go it alone, they clearly have no idea how much time and resources it takes to progress a company with a pipeline of products like hemo through to commercialisation. It takes 10's, actually 100's of millions of dollars. I doubt JHFH and his mates have that sort of cash. So no, HEMO cant go it alone. They need to be brought out and get there technology into BP hands who can progress it all at relatively lightning fast speeds. After all, this is the best thing for patients right????

Hemo will be brought out, how much for depends on getting more than one bidder. Something Vlad might actually succeed at as he focuses on the science only and personally I think he'd have issued warrants and diluted to oblivion for as long as it took without JHFH and his mates APPROACHING HIM.

Has Vlad taken these steps? I think he was approached by JHFH and others not the other way around. He was happy burying his head in the sand focusing on the science. For company to be investment ready, it needs a bigger market cap also. Something he hasn't cared about for as long as I can remember and I was invested here a few years back but thankfully cut my losses at the time quite short.

Vlad is no commercial genius, let's not make out he is.

Yes because why would big pharma give hemo enough cash so that they can become a beast themselves. They won't. They'll just buy it. As long as data continues to impress its a shoo in and I say that as a very cautious investor. Shares will just be suspended one day and thats it. Could be anytime but most likely by end Q1 2026 at the latest

Also, no licence deal will come, hemo will be brought out. Its what big pharma do. Their modus operandi...

Need to get a move on with cohort 2 and the pediatrics as I feel with some data in the bag from these is all it will take.

Good points JHFH, im not saying HEMO isnt investment ready or that it is. What im saying is they haven't been invited to present BECAUSE they are investment ready or I seriously doubt that anyway.

So on my question about webinar, can you clarify for me/us all please whether he's going to come out and give us something?

Moorscloud, do you just believe everything AI spits out? Come on. Use your own brain you can make AI say what you want. Not saying Haywain as done that but are we really to believe every company there have been selected because they're investment ready? ? Doubt it.

Its a conference to share scientific results thats all. However there are attendees who would look to invest as there is at all these types of events. People on the sniff for bargain biotechs that are under the radar. Sounds a lot like what HEMO is to me. Doesn't mean they've been selected because they are "investment ready"

Bid lifted again, won't be long now... ;-)

JHFH, you have connections with vlad, right? Has he been convinced to out on some kind of webinar soon? I know you said he's busy but that doesn't cut it for me. He's CEO and its his responsibility to engage with shareholders and to protect the value of the company. On the back of today's news and imminent cohort 1 release plus immediate move into pediatrics on the horizon there is a lot to discuss...

Dr Tap is presenting p1a data right, not p1b data. Can I just confirm.

P1b data is what will unlock the commercial deal(s)

This happens when a stock makes a big move, and then consolidates with each pullback smaller than the previous and pullbacks are experienced with less volume before it breaks out ideally with volume.

Price is coiling here almost perfectly and with news due it appears to be set up really well. Its all about probability not certainty though. Right now high probability this breaks to the upside and with so few shares in circulation circa 5m, the move could be rapid.

People rely on AI too much. I dont agree this means its "investment ready" but it does imply to me that for HEMO to accept, that they have something worth sharing of great scientific interest

Very positive indeed. Is this an oral presentation does anyone know?

Note attendees are:- policymakers, investors, corporate leaders, and innovators

Could garner some interest, especially if we have good data for all 3 patients. Will Vlad be sharing this presentation to us retail investors ? Hemo really ought too

Wow, those shorts open sub 400p ?! Crazy.

One thing with being short is your losses are effectively infinite if left. Always should use a tight stop and research to death before putting one on. Ive used them a few times (not here contrary to popular belief) and you can very quickly get in a big mess. Im shocked.

And i also think it's morally questionable at the least to short a stock such as this. Hope they burn personally

Thanks for sharing Tilly

Pumpkin I looked at Roq today following your post here about their tumour targeting oral tablet. Interesting tech. Looks promising however I would strongly encourage you to look at Avacta's precision platform. I did an AI comparison of the two plus a bit of basic research and coupled it with what I already know about avacta and in a nutshell, pre|CISION knocks the socks off it every which way. Its currently being compared against standard chemo but you really need to compare it against new and upcoming technology to get a true sense of its potential.

I think everybody knows and agrees that standard chemo is dreadful and we need alternative treatments BUT... if you can retain the potency of chemo whilst eliminating all the side effects, you have a total game changer because chemo is actually incredibly potent and good at fighting cancer. The problem is its side effects which pre|CISION masks.

Have a look at them mate 👍